{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:06:44Z","timestamp":1792843604162,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Clinical Research Fund For Distinguished Young Scholars of Beijing Cancer Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1245\/s10434-026-19139-6","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:18:49Z","timestamp":1775240329000},"page":"5950-5957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoadjuvant Combination Therapy with Tyrosine Kinase and Immune Checkpoint Inhibitors in Anaplastic Thyroid Cancer: A Single-Center, Real-World Experience"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-7558","authenticated-orcid":false,"given":"Yuntao","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"19139_CR1","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin B, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res. 2019;11:5888\u201396.","journal-title":"Am J Transl Res."},{"key":"19139_CR2","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"Smallridge RC, et al. American thyroid association anaplastic thyroid cancer guidelines taskforce. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22:1104\u201339. https:\/\/doi.org\/10.1089\/thy.2012.0302.","journal-title":"Thyroid."},{"key":"19139_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33:406\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014.","journal-title":"Ann Oncol."},{"key":"19139_CR4","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2022.07.1726","volume":"33","author":"C Dierks","year":"2022","unstructured":"Dierks C, et al. 1646MO Phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann Oncol. 2022;33:S1295. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1726.","journal-title":"Ann Oncol."},{"key":"19139_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s12020-023-03390-y","volume":"81","author":"X Zheng","year":"2023","unstructured":"Zheng X, et al. Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma. Endocrine. 2023;81:540\u20136. https:\/\/doi.org\/10.1007\/s12020-023-03390-y.","journal-title":"Endocrine."},{"key":"19139_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, et al. Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid. 2024;34:336\u201346. https:\/\/doi.org\/10.1089\/thy.2023.0573.","journal-title":"Thyroid."},{"key":"19139_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1177\/10507256251372191","volume":"35","author":"S Kini","year":"2025","unstructured":"Kini S, et al. Immunotherapy in initial treatment of anaplastic thyroid cancer: evaluation of overall survival in a National Cancer Database study. Thyroid. 2025;35:1129\u201337. https:\/\/doi.org\/10.1177\/10507256251372191.","journal-title":"Thyroid."},{"key":"19139_CR8","doi-asserted-by":"publisher","first-page":"8397","DOI":"10.1002\/cam4.3450","volume":"9","author":"Y Song","year":"2020","unstructured":"Song Y, et al. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: a prospective blinded single-center study in China. Cancer Med. 2020;9:8397\u2013405. https:\/\/doi.org\/10.1002\/cam4.3450.","journal-title":"Cancer Med."},{"key":"19139_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS6105","author":"AH Abdelhamid Ahmed","year":"2023","unstructured":"Abdelhamid Ahmed AH, et al. A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS6105.","journal-title":"J Clin Oncol."},{"key":"19139_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"Zhao X, et al. Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E-mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid. 2023;33:484\u201391. https:\/\/doi.org\/10.1089\/thy.2022.0504.","journal-title":"Thyroid."},{"key":"19139_CR11","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/hed.27735","volume":"46","author":"M Russell","year":"2024","unstructured":"Russell M, et al. Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience. Head Neck. 2024;46:2496\u2013507. https:\/\/doi.org\/10.1002\/hed.27735.","journal-title":"Head Neck."},{"key":"19139_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/jamaoncol.2024.2133","volume":"10","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, et al. Initial management of BRAF V600E-variant anaplastic thyroid cancer: the FAST Multidisciplinary Group Consensus statement. JAMA Oncol. 2024;10:1264\u201371. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2133.","journal-title":"JAMA Oncol."},{"key":"19139_CR13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"Wang JR, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid. 2019;29:1036\u201343. https:\/\/doi.org\/10.1089\/thy.2019.0133.","journal-title":"Thyroid."},{"key":"19139_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00504","volume":"6","author":"JR Wang","year":"2022","unstructured":"Wang JR, et al. Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma. JCO Precis Oncol. 2022;6:e2100504. https:\/\/doi.org\/10.1200\/PO.21.00504.","journal-title":"JCO Precis Oncol."},{"key":"19139_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1089\/thy.2025.0044","volume":"35","author":"ME Cabanillas","year":"2025","unstructured":"Cabanillas ME, et al. Reimagining the therapeutic approach for anaplastic thyroid cancer: the roadmap to a cure. Thyroid. 2025;35:462\u201370. https:\/\/doi.org\/10.1089\/thy.2025.0044.","journal-title":"Thyroid."},{"key":"19139_CR16","doi-asserted-by":"publisher","first-page":"107067","DOI":"10.1016\/j.oraloncology.2024.107067","volume":"159","author":"Y Song","year":"2024","unstructured":"Song Y, et al. Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: a retrospective single-center study. Oral Oncol. 2024;159:107067. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.107067.","journal-title":"Oral Oncol."},{"key":"19139_CR17","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-25-0212.2025Sep18:ETJ-25-0212","volume":"14","author":"H Katoh","year":"2025","unstructured":"Katoh H, et al. Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion. Eur Thyroid J. 2025;14:e250212. https:\/\/doi.org\/10.1530\/ETJ-25-0212.2025Sep18:ETJ-25-0212.","journal-title":"Eur Thyroid J."},{"key":"19139_CR18","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1089\/thy.2020.0296","volume":"31","author":"Y Qin","year":"2021","unstructured":"Qin Y, et al. Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma. Thyroid. 2021;31:1235\u201343. https:\/\/doi.org\/10.1089\/thy.2020.0296.","journal-title":"Thyroid."},{"key":"19139_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7.","journal-title":"J Hematol Oncol."},{"key":"19139_CR20","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","volume":"27","author":"D Li","year":"2021","unstructured":"Li D, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021;27:3567\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2950.","journal-title":"Clin Cancer Res."},{"key":"19139_CR21","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-22-3406","volume":"29","author":"Y Chi","year":"2023","unstructured":"Chi Y, et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase II trial. Clin Cancer Res. 2023;29:4047\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3406.","journal-title":"Clin Cancer Res."},{"key":"19139_CR22","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"Wirth LJ, et al. Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol. 2021;39:2359\u201366. https:\/\/doi.org\/10.1200\/JCO.20.03093.","journal-title":"J Clin Oncol."},{"key":"19139_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6008","author":"M Zafereo","year":"2025","unstructured":"Zafereo M, et al. Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC): a multicenter phase 2 trial. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.6008.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19139-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19139-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19139-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:51:41Z","timestamp":1780761101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19139-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19139"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19139-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies were reviewed and approved by the Institutional Review Board (IRB) of Peking University Cancer Hospital (Approval No. The ethics committee waived the need for written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}